(GXI) Gerresheimer - Overview
Stock: Prefillable Syringes, Glass Vials, Plastic Containers, Inhalers, Ampoules
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.08% |
| Yield on Cost 5y | 0.05% |
| Yield CAGR 5y | -57.71% |
| Payout Consistency | 83.6% |
| Payout Ratio | 2.0% |
| Risk 5d forecast | |
|---|---|
| Volatility | 44.9% |
| Relative Tail Risk | -11.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.98 |
| Alpha | -75.72 |
| Character TTM | |
|---|---|
| Beta | 0.351 |
| Beta Downside | 0.877 |
| Drawdowns 3y | |
|---|---|
| Max DD | 80.38% |
| CAGR/Max DD | -0.39 |
Description: GXI Gerresheimer January 15, 2026
Gerresheimer AG (XETRA:GXI) is a German-based global supplier of pharmaceutical and medical packaging, operating through three segments: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. Its product portfolio spans pre-fillable syringes, glass vials, ampoules, bottles, caps, inhalers, auto-injectors, point-of-care diagnostics, and cosmetic containers, serving pharma, biotech, med-tech, diagnostics, cosmetics, and food-beverage customers.
Key recent metrics (derived from the FY 2023 annual report, assumed to be the latest public data) show revenue of roughly €2.3 billion, an operating margin of about 8 %, and a 5 % year-over-year increase in glass primary-packaging volumes driven by the surge in biologics and vaccine production. Capital expenditures in 2023 were €150 million, primarily allocated to expanding glass-forming capacity in Europe and the United States, reflecting the sector’s shift toward glass for high-value biologics.
Sector-level drivers that materially affect Gerresheimer include the aging global population (raising demand for injectable therapies), the rapid growth of biologics and cell-based medicines (which favor glass over plastic for stability), and tightening regulatory standards on sterility and traceability that increase reliance on integrated, contract-manufacturing solutions.
For a deeper, data-driven assessment of GXI’s valuation and risk profile, the ValueRay analysis provides a concise, decision-ready overview.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: 23.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA 1.54 > 1.0 |
| NWC/Revenue: -0.83% < 20% (prev -10.56%; Δ 9.72% < -1%) |
| CFO/TA 0.05 > 3% & CFO 253.6m > Net Income 23.4m |
| Net Debt (2.16b) to EBITDA (394.9m): 5.48 < 3 |
| Current Ratio: 0.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (34.5m) vs 12m ago 0.0% < -2% |
| Gross Margin: 26.89% > 18% (prev 0.29%; Δ 2660 % > 0.5%) |
| Asset Turnover: 54.55% > 50% (prev 56.47%; Δ -1.92% > 0%) |
| Interest Coverage Ratio: 1.33 > 6 (EBITDA TTM 394.9m / Interest Expense TTM 106.9m) |
Altman Z'' 0.92
| A: -0.00 (Total Current Assets 1.09b - Total Current Liabilities 1.11b) / Total Assets 4.69b |
| B: 0.16 (Retained Earnings 734.2m / Total Assets 4.69b) |
| C: 0.03 (EBIT TTM 142.0m / Avg Total Assets 4.13b) |
| D: 0.19 (Book Value of Equity 623.4m / Total Liabilities 3.26b) |
| Altman-Z'' Score: 0.92 = BB |
Beneish M -2.95
| DSRI: 0.92 (Receivables 291.1m/281.9m, Revenue 2.25b/2.01b) |
| GMI: 1.08 (GM 26.89% / 29.09%) |
| AQI: 1.05 (AQ_t 0.38 / AQ_t-1 0.36) |
| SGI: 1.12 (Revenue 2.25b / 2.01b) |
| TATA: -0.05 (NI 23.4m - CFO 253.6m) / TA 4.69b) |
| Beneish M-Score: -2.95 (Cap -4..+1) = A |
What is the price of GXI shares?
Over the past week, the price has changed by +1.74%, over one month by -8.03%, over three months by +2.15% and over the past year by -64.50%.
Is GXI a buy, sell or hold?
What are the forecasts/targets for the GXI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 34.2 | 33.2% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 21.6 | -15.8% |
GXI Fundamental Data Overview February 03, 2026
P/E Trailing = 37.0882
P/E Forward = 7.1429
P/S = 0.3871
P/B = 0.6317
Revenue TTM = 2.25b EUR
EBIT TTM = 142.0m EUR
EBITDA TTM = 394.9m EUR
Long Term Debt = 1.71b EUR (from longTermDebt, last quarter)
Short Term Debt = 604.9m EUR (from shortTermDebt, last quarter)
Debt = 2.31b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.16b EUR (from netDebt column, last quarter)
Enterprise Value = 3.04b EUR (871.1m + Debt 2.31b - CCE 145.9m)
Interest Coverage Ratio = 1.33 (Ebit TTM 142.0m / Interest Expense TTM 106.9m)
EV/FCF = -35.01x (Enterprise Value 3.04b / FCF TTM -86.7m)
FCF Yield = -2.86% (FCF TTM -86.7m / Enterprise Value 3.04b)
FCF Margin = -3.85% (FCF TTM -86.7m / Revenue TTM 2.25b)
Net Margin = 1.04% (Net Income TTM 23.4m / Revenue TTM 2.25b)
Gross Margin = 26.89% ((Revenue TTM 2.25b - Cost of Revenue TTM 1.65b) / Revenue TTM)
Gross Margin QoQ = 24.77% (prev 26.28%)
Tobins Q-Ratio = 0.65 (Enterprise Value 3.04b / Total Assets 4.69b)
Interest Expense / Debt = 1.01% (Interest Expense 23.4m / Debt 2.31b)
Taxrate = 23.50% (34.5m / 146.8m)
NOPAT = 108.6m (EBIT 142.0m * (1 - 23.50%))
Current Ratio = 0.98 (Total Current Assets 1.09b / Total Current Liabilities 1.11b)
Debt / Equity = 1.65 (Debt 2.31b / totalStockholderEquity, last quarter 1.40b)
Debt / EBITDA = 5.48 (Net Debt 2.16b / EBITDA 394.9m)
Debt / FCF = -24.96 (negative FCF - burning cash) (Net Debt 2.16b / FCF TTM -86.7m)
Total Stockholder Equity = 1.47b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.57% (Net Income 23.4m / Total Assets 4.69b)
RoE = 1.59% (Net Income TTM 23.4m / Total Stockholder Equity 1.47b)
RoCE = 4.48% (EBIT 142.0m / Capital Employed (Equity 1.47b + L.T.Debt 1.71b))
RoIC = 5.74% (NOPAT 108.6m / Invested Capital 1.89b)
WACC = 2.54% (E(871.1m)/V(3.18b) * Re(7.21%) + D(2.31b)/V(3.18b) * Rd(1.01%) * (1-Tc(0.23)))
Discount Rate = 7.21% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
Fair Price DCF = unknown (Cash Flow -86.7m)
EPS Correlation: -4.30 | EPS CAGR: -15.01% | SUE: -0.69 | # QB: 0
Revenue Correlation: 78.68 | Revenue CAGR: 6.93% | SUE: -0.20 | # QB: 0
EPS next Year (2026-11-30): EPS=3.43 | Chg30d=-0.060 | Revisions Net=+0 | Growth EPS=+5.6% | Growth Revenue=+4.1%